Biohaven (BHVN) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.78

Estimate

-$0.61

Surprise

-27.6%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Biohaven (BHVN) reported a wider loss than forecast — adjusted EPS of -$0.78 against the -$0.61 estimate (a 27.6% shortfall).

TrendMatrix currently rates BHVN Sell at 5.2/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's -27.6% surprise compares with a -1.8% four-quarter average. Next scheduled report: 2026-11-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$13.48

Price target

$19.14

Stop

$12.54

Upside to target

+41.9%

Reward-to-risk

2.8:1

Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.06B

P/E (fwd)

-7.3

52-week range

$7.48–$18.57

Off 52-week high

27.4%

RSI (14)

37

Volume vs avg

0.59×

Score today

5.2/10